Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 20/20 | 0.77 |
| ▸ | JAK2 | O60674 | 9/20 | 0.75 |
| ▸ | JAK1 | P23458 | 9/20 | 0.75 |
| ▸ | TYK2 | P29597 | 4/20 | 0.75 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.69 |
| ▸ | MARK3 | P27448 | 2/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.69 |
| ▸ | STK3 | Q13188 | 2/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.69 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.69 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.69 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.69 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.69 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | FYN | P06241 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242435 | 0.91 | JAK3 (0.72) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4070007 | 0.91 | JAK3 (0.75) | JAK3JAK2JAK1TYK2PKN2 | |
| Benzamide SCHEMBL28763318 | 0.90 | JAK3 (0.71) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4061347 | 0.89 | JAK3 (0.71) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL2365606 | 0.89 | JAK3 (0.81) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4062775 | 0.89 | JAK3 (0.81) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL27676909 | 0.89 | JAK3 (0.70) | JAK3JAK2JAK1TYK2PKN2 | |
| Biphenyl SCHEMBL28763309 | 0.89 | JAK3 (0.75) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL5332305 | 0.88 | JAK3 (0.71) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL4066276 | 0.87 | JAK3 (0.70) | JAK3JAK2JAK1TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686130-B1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | PFIZER PROD INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-7192963-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1686130-A1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | Pfizer Products Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1294724-B1 | PYRROLO¬2,3-D|PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6962993-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2005-09-08 | — | — | US | disclosed |
| US-6696567-B2 | INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | JAK3 3/4885JAK2 6/4885JAK1 1/4885 |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | CDK2, CDK3, JAK3 | JAK3 3/4885JAK2 4/4885JAK1 5/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | JAK3 3/4885JAK2 6/4885JAK1 1/4885 |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | CDK2, CDK3, JAK3 | JAK3 3/4885JAK2 4/4885JAK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.